Plasma ofCS‐modified CD44 predicts the survival of patients with lung cancer

Abstract

AbstractPlasma levels of oncofetal chondroitin sulfate (ofCS)‐modified CD44 have emerged as a promising biomarker for multi‐cancer detection. Here, we explored its potential to predict the survival of patients with lung cancer. A prospective observational cohort was conducted involving 274 newly diagnosed patients with lung cancer at the Sun Yat‐sen University Cancer Center from 2013 to 2015. The plasma levels of ofCS‐modified CD44 were measured, and Cox regression analysis was performed to assess the association between plasma‐modified CD44 levels and overall survival (OS) as well as other prognostic outcomes. Prognostic nomograms were constructed based on plasma ofCS‐modified CD44 levels to predict survival outcomes for patients with lung cancer. Patients with high expression ofCS‐modified CD44 exhibited significantly worse outcomes in terms of OS (HR = 1.61, 95%CI = 1.13–2.29, p = 0.009) and progression‐free survival (PFS). These findings were consistent across various analyses. The concordance index of the prognostic nomogram for predicting OS in both the training set and validation set were 0.723 and 0.737, respectively. Additionally, time‐dependent receiver operating characteristic (ROC) curves showed that the nomogram could serve as a useful tool for predicting OS in patients with lung cancer. Plasma ofCS‐modified CD44 may serve as an independent prognosis marker for patients with lung cancer. Further validation of its predictive value could enhance prognostic assessment and guide personalized treatment strategies for patients with lung cancer.